Arbutus Biopharma Corporation (ABUS) News

Arbutus Biopharma Corporation (ABUS): $2.34

0.03 (+1.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ABUS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 395

in industry

Filter ABUS News Items

ABUS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ABUS News Highlights

  • For ABUS, its 30 day story count is now at 5.
  • Over the past 26 days, the trend for ABUS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about ABUS are CF, DCPH and HALO.

Latest ABUS News From Around the Web

Below are the latest news stories about Arbutus Biopharma Corp that investors may wish to consider to help them evaluate ABUS as an investment opportunity.

Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 5% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 22, 2022

Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate Update

WARMINSTER, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its fourth quarter and year end 2021 financial results and corporate update for Thursday, March 3, 2022. The schedule for the press release and conference call/webcast are as follows: •Q4 and Year End 2021 Press

Yahoo | February 17, 2022

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -1.34% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 8, 2022

What's the Outlook for Arbutus Biopharma?

The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing.

Yahoo | February 5, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, trader!

William White on InvestorPlace | January 31, 2022

First Quadrant L P Buys Innoviva Inc, NOW Inc, General Electric Co, Sells , Brookfield Asset ...

Investment company First Quadrant L P (Current Portfolio) buys Innoviva Inc, NOW Inc, General Electric Co, CF Industries Holdings Inc, JPMorgan Chase, sells , Brookfield Asset Management Inc, , Roku Inc, Cardiovascular Systems Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First Quadrant L P.

Yahoo | January 27, 2022

Arbutus Biopharma outlines milestones for 2022

Arbutus Biopharma (ABUS) announces its 2022 corporate objectives and provided a financial update

Seeking Alpha | January 24, 2022

Arbutus Announces 2022 Corporate Objectives and Provides Financial Update

Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies Complete IND-enabling studies for oral PD-L1 inhibitor, AB-101, for the treatment of HBV Complete IND-enabling studies for next generation oral RNA destabilizer, AB-161, for the treatment of HBVAdvance an nsp5 main protease (Mpro) inhibitor candidate into IND-enabling studies for treatment of SARS-CoV-2 Financial position significantly strengthened; cash runway into Q2

Yahoo | January 24, 2022

Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

Yahoo | January 5, 2022

Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference

WARMINSTER, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with chronic hepatitis B virus infection and to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright Bioconnect Virtua

Yahoo | January 4, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5617 seconds.